Publications — Cardiovascular & Clinical Pharmacology Research

2026

7 publications

01
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial · Nature Medicine
doi:10.1038/s41591-025-04090-y PubMed 41507574
02
Twenty‐Four‐Hour Central Ambulatory Blood Pressure: Relationship With Measures of Cardiovascular Subclinical Organ Damage in Healthy Individuals · Journal of the American Heart Association
doi:10.1161/jaha.124.042788 PubMed 41467406
03
Measuring cardiac stroke volume through in-ear audio sensing · Nature communications
doi:10.1038/s41467-026-75642-0 PubMed 42469245
04
GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA) · BMJ open respiratory research
doi:10.1136/bmjresp-2025-004075 PubMed 42350075
05
Left atrial stiffness, exercise intolerance and injury biomarkers predict adverse outcomes in patients with heart failure with preserved ejection fraction · NPJ cardiovascular health
doi:10.1038/s44325-026-00138-1 PubMed 42270830
06
Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide" · American journal of cardiovascular drugs : drugs, devices, and other interventions
doi:10.1007/s40256-026-00800-0 PubMed 42151688
07
The predictive value of left atrioventricular coupling index for ILR-detected atrial fibrillation following an embolic stroke of undetermined source in patients with sinus rhythm · European heart journal. Imaging methods and practice
doi:10.1093/ehjimp/qyag065 PubMed 42136910

2025

9 publications

01
An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects · British Journal of Clinical Pharmacology
doi:10.1002/bcp.70282 PubMed 41025322
02
Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide · American Journal of Cardiovascular Drugs
doi:10.1007/s40256-025-00743-y PubMed 40889093
03
Isometric exercise training in patients with heart failure with preserved ejection fraction: A randomised controlled study · European Journal of Preventive Cardiology
doi:10.1093/eurjpc/zwaf541 PubMed 40874462
04
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension · JAMA
doi:10.1001/jama.2025.9413
05
Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes · Scientific Reports
doi:10.1038/s41598-025-04559-3 PubMed 40593987
06
Low-dose interleukin-2 induces clonal expansion of BACH2-repressed effector regulatory T cells following acute coronary syndrome · Nature Cardiovascular Research
doi:10.1038/s44161-025-00652-y PubMed 40461772
07
Cardiac Structure, Function and Mechanics in Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis · Hypertension
doi:10.1161/hypertensionaha.124.24472 PubMed 40365671
08
A pathway toward clinical translation of hyperpolarized [1,4‐<scp>13C2</scp>,2,3‐d2]fumarate as an imaging biomarker for early cellular necrosis in vivo · Magnetic Resonance in Medicine
doi:10.1002/mrm.30519 PubMed 40331406
09
Dysregulation of lipid mediators in patients with frequent exacerbations of COPD · ERJ Open Research
doi:10.1183/23120541.00950-2023 PubMed 40129548

2023

4 publications

01
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial · The Lancet Respiratory Medicine
doi:10.1016/s2213-2600(23)00376-4 PubMed 37977159
02
Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges · Frontiers in Pharmacology
doi:10.3389/fphar.2023.1219591 PubMed 38026971
03
Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA · BMJ Open Respiratory Research
doi:10.1136/bmjresp-2022-001601 PubMed 37316306
04
Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells · Nature Communications
doi:10.1038/s41467-023-37424-w PubMed 37045832

2022

5 publications

01
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study · BMC Cardiovascular Disorders
doi:10.1186/s12872-021-02407-6 PubMed 35152886
02
Low-doseinterleukin 2 for the reduction ofvascular inflammation in acute coronarysyndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial · BMJ Open
doi:10.1136/bmjopen-2022-062602 PubMed 36207050
03
Evaluation of Dynamic <scp>Contrast‐Enhanced MRI</scp> Measures of Lung Congestion and Endothelial Permeability in Heart Failure: A Prospective Method Validation Study · Journal of Magnetic Resonance Imaging
doi:10.1002/jmri.28174 PubMed 35343008
04
Niclosamide—A promising treatment for COVID‐19 · British Journal of Pharmacology
doi:10.1111/bph.15843 PubMed 35348204
05
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19 · Journal of Molecular and Cellular Cardiology
doi:10.1016/j.yjmcc.2022.03.007 PubMed 35339512

2021

9 publications

01
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease · NEJM Evidence
doi:10.1056/evidoa2100009 PubMed 38319239
02
Baricitinib set to join the Covid-19 therapeutic arsenal? · Rheumatology (Bulgaria)
doi:10.1093/rheumatology/keab061 PubMed 33502499
03
Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis · BJGP Open
doi:10.3399/bjgpo.2021.0094 PubMed 34465577
04
Diagnosis of patients with heart failure with preserved ejection fraction in primary care: cohort study · ESC Heart Failure
doi:10.1002/ehf2.13612
05
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19 · Pulmonary Pharmacology and Therapeutics
doi:10.1016/j.pupt.2021.102035 PubMed 33933611
06
Innate Lymphoid Cells Promote Recovery of Ventricular Function After Myocardial Infarction · Journal of the American College of Cardiology
doi:10.1016/j.jacc.2021.07.018 PubMed 34503682
07
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): Protocol and study rationale for a randomised, open label, parallel group, mechanistic study · BMJ Open
doi:10.1136/bmjopen-2020-037457 PubMed 33849844
08
Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial · Hypertension
doi:10.1161/hypertensionaha.120.16454 PubMed 33775123
09
Quantitative18 f-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in copd · ERJ Open Research
doi:10.1183/23120541.00699-2020 PubMed 34476245

2020

11 publications

2019

6 publications

01
Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. · Scientific reports
doi:10.1038/s41598-019-56157-9 PubMed 31882594
02
Reproducibility of compartmental modelling of 18F-FDG PET/CT to evaluate lung inflammation. · EJNMMI physics
doi:10.1186/s40658-019-0265-8 PubMed 31844995
03
Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers - a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. · Journal of drug assessment
doi:10.1080/21556660.2019.1677673 PubMed 31692938
04
Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double-blind, placebo-controlled study · British Journal of Clinical Pharmacology
doi:10.1111/bcp.13748 PubMed 30161291
05
Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects · American Journal of Cardiovascular Drugs
doi:10.1007/s40256-018-00320-6 PubMed 30637626
06
Non-invasive measurements of arterial function: What? When? Why should we use them? · Heart
doi:10.1136/heartjnl-2018-312970 PubMed 30826771

2018

8 publications

2017

4 publications

01
Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation · EJNMMI Research
doi:10.1186/s13550-017-0291-2 PubMed 28547129
02
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers · Chest
doi:10.1016/j.chest.2016.10.058 PubMed 27884766
03
[Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13 · Frontiers in Neuroscience
doi:10.3389/fnins.2017.00092 PubMed 28293165
04
Quantification of Lung PET Images: Challenges and Opportunities · Journal of Nuclear Medicine
doi:10.2967/jnumed.116.184796 PubMed 28082432

2016

3 publications

01
Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor · British Journal of Clinical Pharmacology
doi:10.1111/bcp.12855 PubMed 26620151
02
Tetrahydrobiopterin supplementation improves endothelial function but does not alter aortic stiffness in patients with rheumatoid arthritis · Journal of the American Heart Association
doi:10.1161/jaha.115.002762 PubMed 26896473
03
The role of the autonomic nervous system in the regulation of aortic stiffness · Hypertension
doi:10.1161/hypertensionaha.116.08035 PubMed 27672029

2015

2 publications

01
Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist · Hypertension
doi:10.1161/hypertensionaha.114.05099 PubMed 25712721
02
The role of epoxyeicosatrienoic acids in the cardiovascular system · British Journal of Clinical Pharmacology
doi:10.1111/bcp.12603 PubMed 25655310

2014

4 publications

01
Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: A randomised controlled trial · PLoS ONE
doi:10.1371/journal.pone.0099070 PubMed 24911964
02
Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen ('EVOLUTION'): RATIONALE and protocol · Artery Research
doi:10.1016/j.artres.2013.10.380
03
Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease · American Journal of Cardiovascular Drugs
doi:10.1007/s40256-014-0063-6 PubMed 24504769
04
Value of haemodynamic profiling to the response of antihypertensive therapy · Artery Research
doi:10.1016/j.artres.2014.07.004

2013

3 publications

01
Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. · British journal of clinical pharmacology
doi:10.1111/bcp.12063 PubMed 23215699
02
Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. · Journal of hypertension
doi:10.1097/hjh.0b013e32835a8eb1 PubMed 23079681
03
Response to letter regarding article, "anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis" · Circulation
doi:10.1161/circulationaha.113.002597

2012

2 publications

01
Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. · Circulation
doi:10.1161/circulationaha.112.120410 PubMed 23095282
02
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. · JACC. Cardiovascular imaging
doi:10.1016/j.jcmg.2012.02.016 PubMed 22974804

2011

2 publications

01
Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. · Circulation
doi:10.1161/circulationaha.110.971986 PubMed 21262998
02
Increased incidence of interatrial block in younger adults with cryptogenic stroke and patent foramen ovale. · Cerebrovascular diseases extra
doi:10.1159/000327346 PubMed 22566981

2010

2 publications

01
Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. · British journal of clinical pharmacology
doi:10.1111/j.1365-2125.2010.03745.x PubMed 21175435
02
Primary prevention of CVD: treating hypertension. · BMJ clinical evidence
PubMed 21733198

2009

2 publications

01
The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. · British journal of clinical pharmacology
doi:10.1111/j.1365-2125.2009.03475.x PubMed 19843055
02
The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. · Journal of hypertension
doi:10.1097/hjh.0b013e32832e0b58 PubMed 19702000

2008

1 publication

01
Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. · International journal of cardiology
doi:10.1016/j.ijcard.2008.02.011 PubMed 18571252

2007

1 publication

01
Role of increased aortic stiffness in the pathogenesis of heart failure · Current Heart Failure Reports
doi:10.1007/s11897-007-0029-y PubMed 17883986

2005

1 publication

01
Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. · Arteriosclerosis, thrombosis, and vascular biology
doi:10.1161/01.atv.0000179599.71086.89 PubMed 16051882

Peer-reviewed research